The city of Cypress, Texas, currently has 1 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: GSK Investigational Site, Cypress, Texas
Conditions: Idiopathic Pulmonary Fibrosis